The marketing in Argentina of a national version of a generic drug for cancer treatment has resulted in significant savings for health insurance and prepaid medical services in the country, with an estimate of between 140 and 160 million dollars annually, according to specialist Eduardo Spitzer. This drug, pembrolizumab, is used in treatments for melanoma, lung cancer, gastric cancer, and other oncological conditions.
The laboratory that held the exclusive patent for this drug for 20 years has seen how other laboratories can now produce generic versions of it. The emergence of a national version manufactured by ELEA has caused a reduction in the selling price of up to 60% since early 2025. This drastic decrease in selling value has been positively received, as pembrolizumab is one of the most prescribed drugs worldwide for the treatment of various types of cancer.
According to Eduardo Spitzer, Scientific Director of ELEA, in statements to the Argentine News Agency, this molecule developed in Argentina is highly effective in oncological treatments and is the result of decades of innovation in the country in the field of monoclonal antibodies. The drug works by inhibiting a protein present in tumors, preventing them from mimicking healthy cells.
Amid the competition that has arisen following the availability of the national generic version, prices have significantly decreased, with substantial discounts offered to maintain market competitiveness. This price drop has been celebrated as a significant advancement in access to oncological treatments in the country.
